![David de Graaf](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David de Graaf is the founder of Reverb Therapeutics, Inc. He is currently serving as an Independent Director at Mediar Therapeutics, Inc. Previously, he held the position of President, Chief Executive Officer & Director at Syntimmune, Inc. and Chief Executive Officer at Abcuro, Inc. From 2018 to 2020, he served as the President & Chief Executive Officer at Comet Therapeutics, Inc. Additionally, he held the position of President, Chief Executive & Scientific Officer at Selventa, Inc. from 2010 to 2014.
Dr. de Graaf obtained a doctorate degree from the University of Illinois.
| Sociétés | Poste | Début |
|---|---|---|
Mediar Therapeutics, Inc.
 Mediar Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics to halt and reverse fibrotic | Directeur/Membre du Conseil | - |
Reverb Therapeutics
 Reverb Therapeutics BiotechnologyHealth Technology Develops cytokine therapies for oncology and auto-immune diseases | Directeur Général | - |
| Sociétés | Poste | Fin |
|---|---|---|
Comet Therapeutics, Inc.
 Comet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders | Directeur Général | 01/07/2020 |
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Engages in developing novel antibody therapies and severe toxicities in bio pharma industry | Directeur Général | 03/01/2018 |
Abcuro, Inc.
 Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Develops bio therapeutics for treatment of autoimmunity and cancer | Directeur Général | - |
Selventa, Inc.
 Selventa, Inc. Miscellaneous Commercial ServicesCommercial Services Develops new approaches for the understanding and treatment of diseases | Président | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 7 |
|---|---|
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Engages in developing novel antibody therapies and severe toxicities in bio pharma industry | Health Technology |
University of Illinois
 University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Selventa, Inc.
Selventa, Inc. Miscellaneous Commercial ServicesCommercial Services Develops new approaches for the understanding and treatment of diseases | Commercial Services |
Abcuro, Inc.
Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Develops bio therapeutics for treatment of autoimmunity and cancer | Commercial Services |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics to halt and reverse fibrotic | Health Technology |
Comet Therapeutics, Inc.
Comet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders | Health Technology |
Reverb Therapeutics
Reverb Therapeutics BiotechnologyHealth Technology Develops cytokine therapies for oncology and auto-immune diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
